StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note released on Thursday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Navidea Biopharmaceuticals has a twelve month low of $0.00 and a twelve month high of $0.17. The stock’s fifty day moving average price […]